Increased Prevalence of Diastolic Heart Failure in Patients with Rheumatoid Arthritis Correlates with Active Disease, but Not with Treatment Type
- PMID: 26373561
- DOI: 10.3899/jrheum.141647
Increased Prevalence of Diastolic Heart Failure in Patients with Rheumatoid Arthritis Correlates with Active Disease, but Not with Treatment Type
Abstract
Objective: Although heart failure (HF) is a major cause of premature mortality, there is little information regarding its prevalence and associated risk factors in patients with rheumatoid arthritis (RA). In this study, we evaluated the prevalence of HF in a community-based RA cohort. Further, we investigated the effect of RA activity and present treatment on HF rate and cardiac structure.
Methods: A diagnostic workup for HF according to the European Society of Cardiology recommendations was performed in 157 patients with RA fulfilling the American College of Rheumatology/European League Against Rheumatism criteria (68% women, age 61 ± 13 yrs) from our outpatient clinic and in 77 age- and sex-matched controls.
Results: The prevalence of HF in patients with RA (24%) was unexpectedly high and differed significantly from the control sample (6%, p = 0.001). Diastolic HF was the dominant type (23% vs 6%), and clinical symptoms alone were of low diagnostic value. Active RA (28-joint Disease Activity Score ≥ 2.6: OR 3.4, 95% CI 1.3-9.8) was an independent risk factor of HF, as well as systemic inflammation (erythrocyte sedimentation rate > 16 mm/h: OR 5.4, 95% CI 2.1-16; C-reactive protein > 10 mg/l: OR 2.6, 95% CI 0.8-8.0) and RA duration > 10 years (OR 2.6, 95% CI 1.2-5.8). HF in RA was associated with concentric hypertrophy (48% vs 17%, p < 0.001) and reduced longitudinal strain (-17.2% vs -19.7%, p < 0.001). However, the prevalence of HF was equivalent between the treatment groups [conventional synthetic disease-modifying antirheumatic drugs (DMARD) 25%, tumor necrosis factor inhibitors 22%, other biological DMARD 27%].
Conclusion: Recognition of all diastolic HF in RA requires a complex diagnostic approach. Active rather than inactive RA places patients at a higher risk for HF, whereas influence of RA treatment on HF risk needs to be elucidated in further studies.
Keywords: CARDIOVASCULAR RISK; CONCENTRIC HYPERTROPHY; DIASTOLIC HEART FAILURE; DISEASE ACTIVITY; GLOBAL LONGITUDINAL STRAIN; RHEUMATOID ARTHRITIS.
Similar articles
-
Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.J Rheumatol. 2006 Feb;33(2):248-55. Epub 2005 Dec 15. J Rheumatol. 2006. PMID: 16358365
-
Databases of patients with early rheumatoid arthritis in the USA.Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S146-53. Clin Exp Rheumatol. 2003. PMID: 14969067 Review.
-
Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis.J Rheumatol. 2015 Nov;42(11):2066-70. doi: 10.3899/jrheum.150478. Epub 2015 Oct 15. J Rheumatol. 2015. PMID: 26472417
-
Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study.J Rheumatol. 2014 Nov;41(11):2129-36. doi: 10.3899/jrheum.131464. Epub 2014 Aug 1. J Rheumatol. 2014. PMID: 25086079
-
Uniform databases in early arthritis: specific measures to complement classification criteria and indices of clinical change.Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S79-88. Clin Exp Rheumatol. 2003. PMID: 14969056 Review.
Cited by
-
Tumor Necrosis Factor Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis.Clin Rev Allergy Immunol. 2023 Dec;65(3):403-419. doi: 10.1007/s12016-023-08975-z. Epub 2023 Dec 29. Clin Rev Allergy Immunol. 2023. PMID: 38157095 Review.
-
Autoimmune Rheumatic Diseases and Vascular Function: The Concept of Autoimmune Atherosclerosis.J Clin Med. 2021 Sep 27;10(19):4427. doi: 10.3390/jcm10194427. J Clin Med. 2021. PMID: 34640445 Free PMC article. Review.
-
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs.Drugs. 2024 Aug;84(8):877-894. doi: 10.1007/s40265-024-02059-8. Epub 2024 Jul 1. Drugs. 2024. PMID: 38949688 Free PMC article. Review.
-
Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance.Drugs Aging. 2016 Jun;33(6):387-98. doi: 10.1007/s40266-016-0374-1. Drugs Aging. 2016. PMID: 27154398 Review.
-
Serum Vitamin D Levels, Disease Activity Score-28 for Rheumatoid Arthritis with C-Reactive Protein (DAS28-CRP), and Cardiac Remodeling Determined by Ventricular Dimensions and Left Atrium Diameter in Patients with Rheumatoid Arthritis: A Prospective Observational Study.Med Sci Monit. 2023 Jan 7;29:e938989. doi: 10.12659/MSM.938989. Med Sci Monit. 2023. PMID: 36609557 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous